Patent · US Active

Targeted mutant interferon-beta and uses thereof

US11236141B2 · kind B2 · utility

3Cited by
4References
16Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMay 12, 2017
Grant dateFeb 1, 2022
Priority date
Expiry dateJan 6, 2038

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates, in part, to chimeric proteins comprising mutant interferon-β and their use as therapeutic agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.